An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

Genentech, Inc.0 sites450 target enrollmentOctober 2002

ConditionsPsoriasis

DrugsRaptiva (efalizumab)

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Psoriasis
Sponsor: Genentech, Inc.
Enrollment: 450
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.

Registry

clinicaltrials.gov

Start Date

October 2002

End Date

July 2004

Last Updated

12 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Genentech, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Signed informed consent
•Previous participation in Study ACD2600g
•For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study